Lytix Biopharma AS has received FDA clearance to initiate a Phase II clinical trial in the US designed to assess the efficacy of its lead candidate LTX-315, a first-in-class oncolytic peptide, in several solid tumor types.
26 January, 2021
Success also de-risks the use of ILP-drug candidates in other medical indications, including the company’s inflammatory bowel disease program.
12 January, 2021